UBS analyst Charles Eden upgraded Novozymes to Neutral from Sell with a DKK 340290 price target. The analyst upgraded the shares ahead of the proposed merger between Novozymes and Chr Hansen.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVZMY:
- Novozymes upgraded to Overweight from Equal Weight at Barclays
- Novozymes upgraded to Buy from Hold at Deutsche Bank
- Novozymes price target lowered to DKK 330 from DKK 360 at Barclays
- Novozymes (NVZMY) Reveals Q4 Dividend: Here’s the Essential Information
- Novozymes upgraded to Buy after pullback at DNB Markets
